Abstract
Histone deacetylases are considered promising epigenetic targets for chemical protein degradation due to their diverse roles in physiological cellular functions and in the diseased state. Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell’s ubiquitin-proteasome system (UPS). One of the promising targets for this approach is histone deacetylase 6 (HDAC6), which is highly expressed in several types of cancers and is linked to the aggressiveness of tumors. In the present work, we describe the synthesis of HDAC6 targeting PROTACs based on previously synthesized benzohydroxamates selectively inhibiting HDAC6 and how to assess their activities in different biochemical in vitro assays and in cellular assays. HDAC inhibition was determined using fluorometric assays, while the degradation ability of the PROTACs was assessed using western blot analysis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16(2):101–114. https://doi.org/10.1038/nrd.2016.211
Pettersson M, Crews CM (2019) PROteolysis TArgeting Chimeras (PROTACs)—past, present and future. Drug Discov Today Technol 31:15–27. https://doi.org/10.1016/j.ddtec.2019.01.002
Itoh Y (2018) Chemical protein degradation approach and its application to epigenetic targets. Chem Rec 18(12):1681–1700. https://doi.org/10.1002/tcr.201800032
Cromm PM, Crews CM (2017) Targeted protein degradation: from chemical biology to drug discovery. Cell Chem Biol 24(9):1181–1190. https://doi.org/10.1016/j.chembiol.2017.05.024
Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci (Lond) 130(12):987–1003. https://doi.org/10.1042/CS20160084
Phimmachanh M, Han JZR, O’Donnell YEI et al (2020) Histone deacetylases and Histone Deacetylase inhibitors in Neuroblastoma. Front Cell Dev Biol 8(1093). https://doi.org/10.3389/fcell.2020.578770
Valenzuela-Fernandez A, Cabrero JR, Serrador JM et al (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18(6):291–297. https://doi.org/10.1016/j.tcb.2008.04.003
Park Y, Lee KS, Park SY et al (2015) Potential prognostic value of Histone Deacetylase 6 and acetylated heat-shock protein 90 in early-stage breast cancer. J Breast Cancer 18(3):249–255. https://doi.org/10.4048/jbc.2015.18.3.249
Bradbury CA, Khanim FL, Hayden R et al (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10):1751–1759. https://doi.org/10.1038/sj.leu.2403910
Sakuma T, Uzawa K, Onda T et al (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29(1):117–124. https://doi.org/10.3892/ijo.29.1.117
Yuan LL, Wang F, Li SL et al (2012) Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 34(6):430–435. https://doi.org/10.3760/cma.j.issn.0253-3766.2012.06.007
Ali A, Zhang F, Maguire A et al (2020) HDAC6 degradation inhibits the growth of high-grade serous ovarian cancer cells. Cancers (Basel) 12(12):3734. https://doi.org/10.3390/cancers12123734
Wu H, Yang K, Zhang Z et al (2019) Development of multifunctional Histone Deacetylase 6 degraders with potent Antimyeloma activity. J Med Chem 62(15):7042–7057. https://doi.org/10.1021/acs.jmedchem.9b00516
Zhang L, Liu N, Xie S et al (2014) HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol Ther 15(11):1561–1570. https://doi.org/10.4161/15384047.2014.956632
Heimburg T, Chakrabarti A, Lancelot J et al (2016) Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of Schistosomiasis. J Med Chem 59(6):2423–2435. https://doi.org/10.1021/acs.jmedchem.5b01478
Heimburg T, Kolbinger FR, Zeyen P et al (2017) Structure-based design and biological characterization of selective Histone Deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity. J Med Chem 60(24):10188–10204. https://doi.org/10.1021/acs.jmedchem.7b01447
Acknowledgments
S.D. acknowledges the funding by a full scholarship from the Ministry of Higher Education of the Arab Republic of Egypt. Funding by the Deutsche Forschungsgemeinschaft DFG (SI868/22-1) is acknowledged.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Darwish, S. et al. (2023). Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras. In: Krämer, O.H. (eds) HDAC/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology, vol 2589. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2788-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2788-4_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2787-7
Online ISBN: 978-1-0716-2788-4
eBook Packages: Springer Protocols